News | Pacemakers | February 13, 2020

FDA Clears Medtronic Micra AV to Treat AV Block

More patients in the U.S. now candidates for a leadless pacing option

The Micra AV leadless pacemaker

February 13, 2020 — The U.S. Food and Drug Administration (FDA) has approval of Micra AV, the world’s smallest pacemaker with atrioventricular (AV) synchrony. The leadless Micra AV device is indicated for the treatment of patients with AV block, a condition in which the electrical signals between the chambers of the heart (the atria and the ventricle) are impaired. 

Medtronic said it now offers the first FDA-approved leadless pacemaker portfolio, expanding the number of potential candidates for this groundbreaking technology in the U.S.

“With the approval of Micra AV, more pacemaker patients qualify for a new treatment option that offers the advantages of leadless pacing – including a minimally invasive implant procedure and a cosmetically invisible device,” said Larry Chinitz, M.D., cardiac electrophysiologist and director of NYU Langone’s Heart Rhythm Center in New York City. “Although complications with traditional pacemakers are infrequent, when they occur, they’re expensive to treat and can be invasive for the patient. Real-world use of Micra has shown a 63% reduction in major complications compared to traditional pacemakers.

Historically, patients with AV block have been treated with traditional dual-chamber pacemakers which are implanted in the upper chest, under the skin below the collar bone, and connected to the heart using thin wires called “leads.” Identical in size and shape to the original Micra Transcatheter Pacing System (TPS), Micra AV has several additional internal atrial sensing algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providing “AV synchronous” pacing therapy to patients with AV block.

The Micra AV leadless pacemaker

 

MARVEL 2 Data Supported FDA Clearance Mica AV to Coordinate Pacing Between the Atrium and Ventricle

The Micra AV approval is based on data from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study, which evaluated the safety and effectiveness of accelerometer-based atrial sensing algorithms. The study evaluated the ability of the Micra’s internal sensor to monitor and detect atrial contractions and enable coordinated pacing between the atrium and ventricle, thereby providing AV synchrony. Results from the study, presented at the American Heart Association 2019 Scientific Sessions and published simultaneously in JACC: Clinical Electrophysiology,[1] showed the primary efficacy objective was met, with a significantly greater percentage of complete heart block patients with normal sinus rhythm having >70% AV synchrony during algorithm-mediated AV synchronous pacing (38 of 40 patients, 95%) than VVI pacing (0 patients, P<0.001 for proportion of patients with >70% synchrony). The study’s primary safety objective was also met, with no pauses or episodes of pacing-induced tachycardia reported during algorithm mediated AV synchronous pacing.

Medtronic will begin training field personnel and physicians, and will activate a limited number of implanting centers in the coming weeks, with full launch anticipated later this spring.

About the Micra Transcatheter Pacing System (TPS)

Approved by the FDA in 2016, the Micra TPS is a leadless pacemaker option for patients who only require pacing in the right ventricle. Comparable in size to a large vitamin, Micra is less than one-tenth the size of traditional pacemakers yet delivers advanced pacing technology to patients via a minimally invasive approach. During the implant procedure, the device is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device.

Unlike traditional pacemakers, Micra does not require leads or a surgical "pocket" under the skin, so potential sources of complications related to leads and pockets are eliminated - as are any visible signs of the device.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. Medtronic strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

View an animation of the Micra AV in use.

For more information: www.medtronic.com

 

Related Micra Leadless Pacemaker Content:

FDA Clears Medtronic Micra AV to Treat AV Block

VIDEO: Current State of Leadless Pacemaker Technology — Interview with Vivek Reddy, M.D.

Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System Detects Atrial Contractions, Restores AV Synchrony

VIDEO: How to Implant the Micra Leadless Pacemaker

New Algorithms in Medtronic Micra Pacemaker May Improve Synchrony and Cardiac Function in AV Block

FDA Approves World's Smallest Pacemaker for U.S. Patients

Safety, Performance of the World's Smallest Pacemaker Reinforced in Real-world Patients

One-Year Results for Micra TPS Pacemaker Trial Presented at ESC 2016

Leadless Pacemaker Gains Medicare Reimbursement

Wireless and Leadless Pacemaker Being Developed by Texas Heart Institute With Federal Grant
 

 

Reference:

1. Clemens Steinwender, Surinder Kaur Khelae, Christophe Garweg, et al. Atrioventricular Synchronous Pacing Using a Leadless Ventricular Pacemaker
Results From the MARVEL 2 Study. JACC: Clinical Electrophysiology. Volume 6, Issue 1, January 2020.DOI: 10.1016/j.jacep.2019.10.017.

 

Related Content

Ventricular Tachycardia Recurrence, Hospitalization and Death Reduced With Catheter Ablation as First Line Therapy. Results from an international clinical trial show a significant reduction in risk of ventricular tachycardia (VT) recurrence, cardiovascular hospitalization, and sudden cardiac death (SCD) death when catheter ablation is used as an early first-line treatment for patients with structural heart disease. Led by study coordinating center, the University of Chicago, The PAUSE-SCD trial. #HRS21
News | EP Lab | August 09, 2021
August 9, 2021 – Results from an international clinical trial show a significant reduction in risk of ventricular tac
Heart Rhythm Society, HRS, 2021 Late-Breaking Clinical Trials in Electrophysiology. #HRS #HRS2021 #HRS21 #Heartrhythm21
Feature | EP Lab | August 09, 2021
July 28, 2021 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of the
An example from the study of the Biosense Webster NuVision 3D/4D ICE imaging capability showing the left atrial appendage (LAA) visualization on 3D ICE. The system allows the user to place a false lighting source to be placed in different positions to change the lighting and shadows to better visualize the anatomy.

An example from the study of the Biosense Webster NuVision 3D/4D ICE imaging capability showing the left atrial appendage (LAA) visualization on 3D ICE. The system allows the user to place a false lighting source to be placed in different positions to change the lighting and shadows to better visualize the anatomy. 

News | EP Lab | August 05, 2021 | By Dave Fornell, Editor
August 5, 2021 —  A prospective, non-randomized, multicenter, first-in-human clinical study found good diagnostic and
EP lab ablation catheter. #HRS21 #HRS2021
News | EP Lab | August 03, 2021
August 3, 2021 — A subgroup analysis of the EAST – AFNET 4 study population revealed early initiation of rhythm contr
emporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study. The TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF) study was presented as a late-breaking study presented at the 2021 Heart Rhythm meeting, the annual conference of the Heart Rhythm Society (HRS).  #HRS21 #HRS2021
News | EP Lab | August 03, 2021
August 4, 2021 — Temporary Spinal cord stimulation (SCS) was effective in suppressing post-operative...
Oral Contraceptives Cause Increased Risk of Cardiac Events in Woman With Long QT Syndrome. #HRS21 #HRS2021 #womenshealth
News | EP Lab | August 03, 2021
August 3, 2021 – Results from a new clinical trial show an increased risk of cardiac events, like sudden cardiac deat
A recent study unveiled a novel sinus node ablation technique that provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021, the annual meeting of the Heart Rhythm Society (HRS). #HRS21 #HRS2021

A novel sinus node ablation technique provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021.

News | EP Lab | August 03, 2021
August 3, 2021 – A recent study unveiled a novel sinus node...
The Philips EPD Kodex system for the EP lab.
News | EP Lab | August 03, 2021
August 3, 2021 – A new analysis of the Catheter Ablation vs.
The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures.

The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures. Photo by Dave Fornell

News | EP Lab | August 03, 2021
August 3, 2021 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnso
The Orchestra BioMed BackBeat Cardiac Neuromodulation Therapy (CNT) system is implanted similar to a pacemaker to stimulate the sympathetic nerves to help reduce blood pressure.

The Orchestra BioMed BackBeat Cardiac Neuromodulation Therapy (CNT) system is implanted similar to a pacemaker to stimulate the sympathetic nerves to help reduce blood pressure.

News | EP Lab | August 03, 2021
August 3, 2021 — Long-term follow-up data on hypertensive patients from the control group of the...